NBIX vs PATH · P/E 45, rev $2.36B vs P/E 19, rev $1.61B
Neurocrine Biosciences Inc (NBIX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NBIX and PATH stock pages for the full models.
Not investment advice.